Oragenics gears up for Phase II trials, appoints new CEO
SARASOTA, Fla. - Oragenics, Inc. (NYSE American: OGEN), a biotechnology firm focusing on brain health and infectious diseases ...
Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections
Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with ...
GlobalData on MSN11d
IO Biotech enrols all subjects in Phase II trial of cancer combination therapy
"IO Biotech enrols all subjects in Phase II trial of cancer combination therapy" was originally created and published by ...
First participants randomized in AskBio Phase II gene therapy trial for Parkinson’s disease
Berlin, Germany, and Research Triangle Park, N.C., USA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Not intended for UK MediaEnrollment ongoing in the ...
Nasdaq7d
AIM ImmunoTech Highlights Clinical Progress and Future Milestones for Ampligen® in Pancreatic Cancer and Long-COVID Therapeutics
Major funding for AIM's clinical trials is being provided by organizations ... Commenced enrollment and dosing in DURIPANC Phase 1b/2 study combining Ampligen with AstraZeneca’s anti-PD-L1 ...
Proactive Investors4y
Synairgen focuses on potentially breakthrough coronavirus treatment now at last stage of trials
Synairgen CEO on funding phase 2 trial for SNG001 - ICYMI Demand for healthcare stocks similar to late 90s tech boom, says analyst Synairgen reaffirms dedication to key asset, says broker ...
PharmiWeb5d
FluoGuide A/S receives approval for phase II trial in head and neck cancer
Copenhagen, Denmark – FluoGuide A/S (“FluoGuide” or the “Company”), a biotech company specializing in precision cancer surgery, announces approval of its phase II Clinical Trial Application for FG001 ...
Business Wire1mon
Anokion Announces the Early Completion of Enrollment in the ACeD-it Phase 2 and the SynCeD Phase 2a Trials of KAN-101 for the Treatment of Celiac Disease
Topline data from both the Phase 2 ACeD-it and Phase 2a SynCeD clinical trials are expected in the ... stage Swiss biotechnology company that aims to make a meaningful difference in the lives ...